{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:11:02Z","timestamp":1777111862424,"version":"3.51.4"},"reference-count":103,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroent\u00e9rologie Clinique et Biologique"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.gcb.2009.03.021","type":"journal-article","created":{"date-parts":[[2009,11,6]],"date-time":"2009-11-06T04:12:36Z","timestamp":1257480756000},"page":"1082-1093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Inflammatory bowel disease and hepatitis\u00a0B and C"],"prefix":"10.1016","volume":"33","author":[{"given":"J.-B.","family":"Chevaux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-A.","family":"Bigard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bensenane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Oussalah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Jarlot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Belle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Nani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-P.","family":"Bronowicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gcb.2009.03.021_bib1","unstructured":"Pr\u00e9valence des h\u00e9patites B et C en France en 2004. Institut de veille sanitaire; 2004."},{"key":"10.1016\/j.gcb.2009.03.021_bib2","first-page":"185","article-title":"Le d\u00e9pistage du VIH, de la syphilis et des h\u00e9patites B et C dans les \u00e9tablissements de transfusion sanguine (ETS)","volume":"39","author":"Pillonel","year":"1992","journal-title":"Bull Epidemiol Hebd"},{"key":"10.1016\/j.gcb.2009.03.021_bib3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJM199707243370404","article-title":"Patient-to-patient transmission of hepatitis C virus during colonoscopy","volume":"337","author":"Bronowicki","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gcb.2009.03.021_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","article-title":"Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)","volume":"109","author":"van Dullemen","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gcb.2009.03.021_bib5","first-page":"A131","article-title":"Achieving long-term maintenance of remission in Crohn's disease: are all anti-TNF created equal? (abstract)","volume":"55 (Suppl.)","author":"Peyrin-Biroulet","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.gcb.2009.03.021_bib6","first-page":"77","article-title":"Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors","volume":"24","author":"Longo","year":"2000","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.gcb.2009.03.021_bib7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00054725-200111000-00002","article-title":"Hepatitis B and C virus infection in Crohn's disease","volume":"7","author":"Biancone","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gcb.2009.03.021_bib8","first-page":"17","article-title":"S\u00e9ropr\u00e9valence de l\u2019infection par le virus C dans un \u00e9chantillon national d\u2019assur\u00e9s sociaux volontaires \u00e0 un examen de sant\u00e9 de la s\u00e9curit\u00e9 sociale","volume":"5","author":"Dubois","year":"1996","journal-title":"Bull Epidemiol Hebd"},{"key":"10.1016\/j.gcb.2009.03.021_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2005.02556.x","article-title":"Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study","volume":"22","author":"Bargiggia","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gcb.2009.03.021_bib10","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2004.040675","article-title":"Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis","volume":"53","author":"Esteve","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.gcb.2009.03.021_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/ajg.2008.4","article-title":"Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study","volume":"104","author":"Loras","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gcb.2009.03.021_bib12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1053\/gast.2002.31602","article-title":"Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection","volume":"122","author":"Biancone","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gcb.2009.03.021_bib13","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/ibd.20216","article-title":"Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease","volume":"13","author":"Colbert","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gcb.2009.03.021_bib14","first-page":"1414","article-title":"Exacerbation of chronic active hepatitis type B after short-term corticosteroid therapy resulting in fatal liver failure","volume":"85","author":"Laskus","year":"1990","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gcb.2009.03.021_bib15","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/jcp.46.11.1004","article-title":"Coexpression of intercellular adhesion molecule-1 and class I major histocompatibility complex antigens on hepatocyte membrane in chronic viral hepatitis","volume":"46","author":"Chu","year":"1993","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.gcb.2009.03.021_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1440-1746.1998.tb00539.x","article-title":"Hepatitis viruses under immunosuppressive agents","volume":"13","author":"Liaw","year":"1998","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib17","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s00535-005-1640-x","article-title":"Disappearance of HCV after cessation of immunosuppression in a patient with ulcerative colitis and renal transplantation","volume":"40","author":"Nagai","year":"2005","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gcb.2009.03.021_bib18","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/gast.2001.22461","article-title":"Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease","volume":"120","author":"Perrillo","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gcb.2009.03.021_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2006.04.015","article-title":"Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy","volume":"131","author":"Hui","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gcb.2009.03.021_bib20","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","article-title":"Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy","volume":"125","author":"Lau","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gcb.2009.03.021_bib21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.21051","article-title":"Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy","volume":"43","author":"Yeo","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.gcb.2009.03.021_bib22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(80)90442-0","article-title":"Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis","volume":"2","author":"Sagnelli","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.gcb.2009.03.021_bib23","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/0042-6822(88)90127-4","article-title":"The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer","volume":"167","author":"Tur-Kaspa","year":"1988","journal-title":"Virology"},{"key":"10.1016\/j.gcb.2009.03.021_bib24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0016-5085(81)80002-9","article-title":"Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B","volume":"81","author":"Scullard","year":"1981","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gcb.2009.03.021_bib25","doi-asserted-by":"crossref","first-page":"A423","DOI":"10.1136\/bmj.39490.680498.BE","article-title":"Fatal reactivation of hepatitis B after chemotherapy for lymphoma (abstract)","volume":"337","author":"Dillon","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.gcb.2009.03.021_bib26","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/sj.bmt.1700744","article-title":"Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study","volume":"19","author":"Lau","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gcb.2009.03.021_bib27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.bmt.1702093","article-title":"Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period","volume":"25","author":"Iwai","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.gcb.2009.03.021_bib28","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/jhep.2003.50220","article-title":"Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma","volume":"37","author":"Cheng","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.gcb.2009.03.021_bib29","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","article-title":"Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study","volume":"100","author":"Lok","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gcb.2009.03.021_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626\u00a0patients with identification of risk factors","volume":"62","author":"Yeo","year":"2000","journal-title":"J Med Virol"},{"key":"10.1016\/j.gcb.2009.03.021_bib31","first-page":"363","article-title":"Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis","volume":"18","author":"Mok","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2133.2007.08058.x","article-title":"Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy","volume":"157","author":"Yang","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib33","first-page":"1002","article-title":"Chemotherapy and immunosuppression in patients with hepatitis B or C","volume":"25","author":"Sitruk","year":"2001","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.gcb.2009.03.021_bib34","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/0016-5085(94)90077-9","article-title":"Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C","volume":"107","author":"Fong","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gcb.2009.03.021_bib35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0192-0561(99)00005-3","article-title":"Effects of corticosteroids on HCV infection","volume":"21","author":"Magy","year":"1999","journal-title":"Int J Immunopharmacol"},{"key":"10.1016\/j.gcb.2009.03.021_bib36","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2007.07.023","article-title":"Influence of steroids on HCV recurrence after liver transplantation: A prospective study","volume":"47","author":"Vivarelli","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib37","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1179\/joc.2006.18.6.662","article-title":"Fatal acute hepatitis C virus infection in patients with hematological malignancies","volume":"18","author":"Taliani","year":"2006","journal-title":"J Chemother"},{"key":"10.1016\/j.gcb.2009.03.021_bib38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hep.1840220107","article-title":"Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro","volume":"22","author":"McMillan","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.gcb.2009.03.021_bib39","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/00007890-199910150-00013","article-title":"The impact of azathioprine on chronic viral hepatitis in renal transplantation: a long-term, single-center, prospective study on azathioprine withdrawal","volume":"68","author":"David-Neto","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.gcb.2009.03.021_bib40","first-page":"385","article-title":"Occurrence and management of hepatitis B virus reactivation following kidney transplantation","volume":"49","author":"Grotz","year":"1998","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.gcb.2009.03.021_bib41","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1097\/00007890-199606270-00019","article-title":"Azathioprine hepatitis in kidney transplant recipients. A predisposing role of chronic viral hepatitis","volume":"61","author":"Pol","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.gcb.2009.03.021_bib42","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/01.TP.0000114610.40412.C6","article-title":"Effect of antimetabolite immunosuppressants on Flaviviridae, including hepatitis C virus","volume":"77","author":"Stangl","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.gcb.2009.03.021_bib43","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1053\/jlts.2001.27803","article-title":"Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: influence of immunosuppressive regimens","volume":"7","author":"Hunt","year":"2001","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gcb.2009.03.021_bib44","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.transproceed.2005.03.045","article-title":"Hepatitis C virus reactivation in anti-hepatitic C virus-positive renal transplant recipients","volume":"37","author":"Melon","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.gcb.2009.03.021_bib45","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.gcb.2007.11.002","article-title":"The liver and methotrexate","volume":"32","author":"Laharie","year":"2008","journal-title":"Gastroenterol Clin Biol"},{"issue":"Suppl. 1","key":"10.1016\/j.gcb.2009.03.021_bib46","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/gut.2005.081950a","article-title":"European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis","volume":"55","author":"Stange","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.gcb.2009.03.021_bib47","first-page":"888","article-title":"Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate","volume":"25","author":"Gwak","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/sj.thj.6200300","article-title":"Severe liver disease is caused by HBV rather than HCV in children with hematological malignancies","volume":"4","author":"El Sayed","year":"2003","journal-title":"Hematol J"},{"key":"10.1016\/j.gcb.2009.03.021_bib49","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/rheumatology\/keh668","article-title":"Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon","volume":"44","author":"Nissen","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.gcb.2009.03.021_bib50","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.11451","article-title":"Hepatitis C and methotrexate","volume":"49","author":"Kujawska","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gcb.2009.03.021_bib51","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gcb.2009.03.021_bib52","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1745-7254.2007.00590.x","article-title":"Evaluation of hepatitis B virus replication and proteomic analysis of HepG2, 2. 15 cell line after cyclosporine A treatment","volume":"28","author":"Xie","year":"2007","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.gcb.2009.03.021_bib53","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/00007890-199003000-00013","article-title":"Hepatitis B liver disease in cyclosporine-treated renal allograft recipients","volume":"49","author":"Huang","year":"1990","journal-title":"Transplantation"},{"key":"10.1016\/j.gcb.2009.03.021_bib54","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1159\/000188635","article-title":"Prevalence and clinical course of hepatitis B and hepatitis C liver disease in ciclosporin-treated renal allograft recipients","volume":"70","author":"Bang","year":"1995","journal-title":"Nephron"},{"key":"10.1016\/j.gcb.2009.03.021_bib55","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1053\/jhep.2003.50449","article-title":"Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes","volume":"38","author":"Watashi","year":"2003","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.gcb.2009.03.021_bib56","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.bcp.2008.12.019","article-title":"Cyclophilin B stimulates RNA synthesis by the HCV RNA dependent RNA polymerase","volume":"77","author":"Heck","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.gcb.2009.03.021_bib57","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1128\/JVI.02614-07","article-title":"Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro","volume":"82","author":"Yang","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.gcb.2009.03.021_bib58","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1016\/j.transproceed.2006.08.055","article-title":"Hepatitis C virus recurrence after liver transplantation: influence of immunosuppressive regimens on viral load and liver histology","volume":"38","author":"Oton","year":"2006","journal-title":"Transplant Proc"},{"issue":"Suppl. 48","key":"10.1016\/j.gcb.2009.03.021_bib59","first-page":"S39","article-title":"HCV infection: pathogenesis, clinical manifestations and therapy","volume":"26","author":"Antonelli","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib60","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gcb.2009.03.021_bib61","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection \u2013 natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gcb.2009.03.021_bib62","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2007.10.011","article-title":"Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection","volume":"38","author":"Carroll","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.gcb.2009.03.021_bib63","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ibd.20035","article-title":"Occult hepatitis B and infliximab-induced HBV reactivation","volume":"13","author":"Madonia","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gcb.2009.03.021_bib64","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jhep.2006.10.007","article-title":"Occult hepatitis B virus infection","volume":"46","author":"Raimondo","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib65","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/rheumatology\/kel123","article-title":"Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis","volume":"45","author":"Roux","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.gcb.2009.03.021_bib66","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0168-8278(99)80060-9","article-title":"Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity","volume":"30","author":"Zylberberg","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib67","first-page":"210","article-title":"Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C","volume":"23","author":"Larrea","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.gcb.2009.03.021_bib68","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2004.11.025","article-title":"Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study","volume":"42","author":"Zein","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib69","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/MCG.0b013e318046ea9a","article-title":"Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice?","volume":"42","author":"Cheung","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gcb.2009.03.021_bib70","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227\u201342.","DOI":"10.1016\/j.jhep.2008.10.001"},{"key":"10.1016\/j.gcb.2009.03.021_bib71","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/gut.2006.114660","article-title":"Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis","volume":"57","author":"Viget","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.gcb.2009.03.021_bib72","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gcb.2009.03.021_bib73","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib74","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1572-0241.2007.01609.x","article-title":"Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases","volume":"103","author":"Worns","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gcb.2009.03.021_bib75","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.gcb.2009.03.021_bib76","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0399-8320(05)80736-5","article-title":"Crohn's disease associated with interferon and ribavirin treatment for chronic hepatitis C","volume":"29","author":"Khalil","year":"2005","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.gcb.2009.03.021_bib77","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/infdis\/151.4.599","article-title":"Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state","volume":"151","author":"McMahon","year":"1985","journal-title":"J Infect Dis"},{"key":"10.1016\/j.gcb.2009.03.021_bib78","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/clinids\/18.3.339","article-title":"Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses","volume":"18","author":"Horvath","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gcb.2009.03.021_bib79","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/j.1440-1746.2006.04559.x","article-title":"Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach","volume":"21","author":"Nathan","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib80","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/00042737-200511000-00015","article-title":"Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases","volume":"17","author":"Villa","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib81","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1136\/gut.52.12.1728","article-title":"A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis","volume":"52","author":"Tilg","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.gcb.2009.03.021_bib82","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/ard.62.7.686","article-title":"Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate","volume":"62","author":"Ostuni","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gcb.2009.03.021_bib83","first-page":"1624","article-title":"Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease","volume":"30","author":"Michel","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib84","first-page":"107","article-title":"Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C","volume":"31","author":"Oniankitan","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib85","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/00054725-200409000-00035","article-title":"Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection","volume":"10","author":"Valle Garcia-Sanchez","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gcb.2009.03.021_bib86","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/ard.2004.031187","article-title":"Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy","volume":"64","author":"Wendling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gcb.2009.03.021_bib87","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10620-005-1295-8","article-title":"Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B","volume":"50","author":"Ueno","year":"2005","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gcb.2009.03.021_bib88","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/art.21216","article-title":"Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab","volume":"52","author":"Anelli","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gcb.2009.03.021_bib89","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3748\/wjg.v12.i6.974","article-title":"Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?","volume":"12","author":"Millonig","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gcb.2009.03.021_bib90","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1478-3231.2007.01665.x","article-title":"Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient","volume":"28","author":"Montiel","year":"2008","journal-title":"Liver Int"},{"key":"10.1016\/j.gcb.2009.03.021_bib91","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00535-008-2165-x","article-title":"Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab","volume":"43","author":"Ojiro","year":"2008","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gcb.2009.03.021_bib92","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00042737-200102000-00016","article-title":"Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection","volume":"13","author":"Campbell","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib93","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/ard.62.11.1078","article-title":"Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection","volume":"62","author":"Peterson","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gcb.2009.03.021_bib94","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1572-0241.2003.07245.x","article-title":"Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF","volume":"98","author":"Holtmann","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gcb.2009.03.021_bib95","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.20702","article-title":"Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection","volume":"51","author":"Parke","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gcb.2009.03.021_bib96","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaad.2004.05.013","article-title":"Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3\u00a0cases","volume":"51","author":"Magliocco","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib97","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jaad.2005.11.1035","article-title":"Etanercept therapy in two patients with psoriasis and concomitant hepatitis C","volume":"54","author":"De Simone","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib98","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaad.2005.05.043","article-title":"Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection","volume":"54","author":"Rokhsar","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib99","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10067-006-0394-z","article-title":"Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases","volume":"26","author":"Aslanidis","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/rheumatology\/kel191","article-title":"Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus","volume":"46","author":"Marotte","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.gcb.2009.03.021_bib101","first-page":"421","article-title":"Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis","volume":"35","author":"Cansu","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib102","first-page":"1944","article-title":"Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection","volume":"35","author":"Ferri","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gcb.2009.03.021_bib103","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5070\/D33627S2B6","article-title":"Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept)","volume":"12","author":"Cecchi","year":"2006","journal-title":"Dermatol Online J"}],"container-title":["Gastroent\u00e9rologie Clinique et Biologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S039983200900339X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S039983200900339X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:48:49Z","timestamp":1759974529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S039983200900339X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":103,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S039983200900339X"],"URL":"https:\/\/doi.org\/10.1016\/j.gcb.2009.03.021","relation":{},"ISSN":["0399-8320"],"issn-type":[{"value":"0399-8320","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammatory bowel disease and hepatitis\u00a0B and C","name":"articletitle","label":"Article Title"},{"value":"Gastroent\u00e9rologie Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gcb.2009.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.gcb.2009.09.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}